GlassScriptPhysician profile
Benedict R Studnicka
NPI 1336198274
$3,600.67
in general payments reported to CMS, 2019-2025
31 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,043 · 2020: $848 · 2021: $666 · 2022: $240 · 2023: $669 · 2024: $15.00 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $772 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $771.61 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $816.32 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $674.42 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $432.98 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $313.65 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $199.68 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $192.91 | 2019-2023 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $177.97 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.55 | 2019-2021 | |
| Medtronic, INC. | $79.70 | 2023 | Interstim |
| Teleflex LLC | $71.31 | 2023 | Urolift |
| Abbvie INC. | $52.47 | 2021-2023 | Dalvance |
| Abbott Laboratories | $47.84 | 2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Arbor Pharmaceuticals, INC. | $45.21 | 2019-2020 | |
| Exact Sciences Corporation | $36.00 | 2023 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $32.89 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $22.32 | 2023 | Arexvy, Shingrix |
| Boston Scientific Corporation | $20.10 | 2019 | |
| Xeris Pharmaceuticals, INC. | $19.15 | 2022 | |
| Eisai INC. | $18.33 | 2020 | |
| Ironwood Pharmaceuticals, INC | $18.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.01 | 2021 | |
| Esperion Therapeutics, INC. | $17.59 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.06 | 2022 | |
| Amgen INC. | $16.80 | 2019 | |
| Dynavax Technologies Corporation | $16.41 | 2023 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $15.53 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.90 | 2019 | |
| Dexcom, INC. | $14.57 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.92 | 2020 | |
| Allergan, INC. | $12.55 | 2020 | |
| Philips North America LLC | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benedict Studnicka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.